Small cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers and are among the most difficult cancers to treat. The cancer may go away with initial treatment, but it often comes back for the majority of SCLC patients.
Stemcentrx’s most advanced drug rovalpituzumab tesirine (Rova-T; SC16LD6.5) is addressing SCLC and other neuroendocrine cancers such as large cell neuroendocrine carcinoma. Rova-T has received orphan drug designation from the FDA for treatment of small cell lung cancer.
Stemcentrx discovered that a novel protein called delta-like protein 3 (DLL3) is present at high levels in SCLC and other neuroendocrine tumor cells. Rova-T is an antibody drug conjugate that is made to target DLL3, enter the tumor cells and release a potent drug to kill these cells. Our targeted approach is designed to reduce the harmful effects on healthy cells.
A pivotal trial with rovalpituzumab tesirine for SCLC in the third line setting and later (NCT02674568) is enrolling. Additional studies in SCLC and other tumor types include a phase 1 study for front-line treatment of SCLC (NCT02819999), a phase 3 study for the second-line treatment of SCLC (NCT03061812), a phase 1/2 study for the treatment of a basket of tumor types (NCT02709889), a phase 1 study for a combination with immunotherapy for the treatment of SCLC (NCT03026166), and a QT study (NCT02874664).
SC-002 is another antibody drug conjugate in development for small cell lung cancer. A Phase 1a clinical trial is ongoing and available for enrollment (NCT02500914).